News >

Pyrotinib Combo Delays Progression in Heavily Pretreated HER2+ Breast Cancer

Jason M. Broderick @jasoncology
Published: Thursday, Aug 22, 2019

breast cancer
Combining the irreversible pan-ErbB inhibitor pyrotinib with capecitabine reduced the risk of disease progression or death by 64% compared with lapatinib (Tykerb) plus capecitabine in Chinese patients with relapsed or metastatic HER2-positive breast cancer who previously received taxanes, anthracyclines, and/or trastuzumab (Herceptin), according to data from a phase II study published in the Journal of Clinical Oncology.

Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study (published online August 20, 2019). J Clin Oncol. doi: 10.1200/JCO.19.00108.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication